Study details
Enrolling now
Exablate for LIFU Neuromodulation in Patients With Opioid Use Disorder (OUD) and/or Other Substance Use Disorders (SUDs)
InSightec
NCT IDNCT04197921ClinicalTrials.gov data as of Apr 2026
Target enrollment
29
Study length
about 7.1 years
Ages
18–60
Locations
4 sites in FL, MD, NY +1
About this study
This trial is testing a device called Exablate Model 4000 Type 2.0/2.1, used with Low Intensity Focused Ultrasound (LIFU), as an additional treatment for Opioid Use Disorder (OUD) and other substance use disorders. The goal is to see if this device is safe and well-tolerated in people with OUD.
Based on ClinicalTrials.gov records.
What participants do
- 1.Use Exablate Model 4000 Type 2.0/2.1
Primary goalOccurrence of Treatment Emergent Adverse Events
Participation effort
Estimated from trial records. Details can vary by site.
Time + visits
Low15%
Logistics
Moderate50%
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Endpoints
Primary: Occurrence of Treatment Emergent Adverse Events
Body systems
Psychiatry / Mental Health